Q-omics provides the consensus-scored TMEM186 profile across patient tissues and cancer cell-line models. TMEM186 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TMEM186 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, TMEM186 RNA expression shows 18,664 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, KIRP, and ACC as cancer lineages where TMEM186 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM186 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM186 survival associations across molecular data types. TMEM186 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM186 RNA expression–survival associations across cancer types. High TMEM186 expression shows unfavorable associations in STAD, LIHC, KIRP and PAAD, but favorable associations in READ and KIRC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify READ as the clearest survival context for TMEM186 RNA expression.
This table summarizes TMEM186 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM186. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM186 shows lower tumor expression in THCA and higher tumor expression in KIRP, COAD, LIHC, LUAD and HNSC. The KIRP box plot shows higher TMEM186 RNA expression in tumor versus normal tissue (log2 FC = +0.697, t-test p < 0.001).
This table shows molecular features associated with TMEM186 in patient tissues and cancer cell lines. In patient samples, TMEM186 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM186 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OESOPHAGUS.
